Our center is a site in a phase IIb trial of a compound named LBR-101. This is a monoclonal antibody directed against calcitonin gene-related peptide (CGRP). Phase I and II trials have been very promising. The medication is given by injection monthly. If CGRP is given by injection in migraineurs, all develop a migraine. If given to non-migraineurs, this does not occur. Further, CGRP in the blood is increased during an attack of migraine. Previous CGRP oral antagonists have all shown efficacy but also possible liver toxicity. Monoclonal antibodies do not have this risk. Inclusion criteria for the trial include at least 8 migraine days a month.
Monoclonal Antibody Treatment of Migraine
Posted in Headache Articles